267420-70-2

Basic information

• Product Name: (2S,4R)-1-tert-butyl 2-Methyl 4-((tert-butyldiMethylsilyl)oxy)-5-oxopyrrolidine-1,2-dicarboxylate
• Synonyms: (2S,4R)-1-tert-butyl 2-Methyl 4-((tert-butyldiMethylsilyl)oxy)-5-oxopyrrolidine-1,2-dicarboxylate
• CAS NO: 267420-70-2
• Molecular Formula: C17H31NO6Si
• Molecular Weight: 373.51664
• Mol File: 267420-70-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2S,4R)-1-tert-butyl 2-Methyl 4-((tert-butyldiMethylsilyl)oxy)-5-oxopyrrolidine-1,2-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4R)-1-tert-butyl 2-Methyl 4-((tert-butyldiMethylsilyl)oxy)-5-oxopyrrolidine-1,2-dicarboxylate(267420-70-2)
• EPA Substance Registry System: (2S,4R)-1-tert-butyl 2-Methyl 4-((tert-butyldiMethylsilyl)oxy)-5-oxopyrrolidine-1,2-dicarboxylate(267420-70-2)

Safety Data

• Hazardous Substances Data: 267420-70-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(2S,4R)-1-tert-butyl 2-Methyl 4-((tert-butyldiMethylsilyl)oxy)-5-oxopyrrolidine-1,2-dicarboxylate is used as a key intermediate in organic synthesis for the development of novel compounds with potential applications in various fields.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (2S,4R)-1-tert-butyl 2-Methyl 4-((tert-butyldiMethylsilyl)oxy)-5-oxopyrrolidine-1,2-dicarboxylate is utilized as a building block for the design and synthesis of new pharmaceutical agents, taking advantage of its unique functional groups and stereochemistry.
Used in Drug Development:
(2S,4R)-1-tert-butyl 2-Methyl 4-((tert-butyldiMethylsilyl)oxy)-5-oxopyrrolidine-1,2-dicarboxylate is employed in drug development as a potential candidate for the treatment of various diseases, given its distinctive molecular features that may offer new therapeutic opportunities.
It is crucial to handle (2S,4R)-1-tert-butyl 2-Methyl 4-((tert-butyldiMethylsilyl)oxy)-5-oxopyrrolidine-1,2-dicarboxylate with care and adhere to safety protocols when working with it in a laboratory environment.

Upstream product

• 186581-53-3 diazomethane 
• 267420-68-8 (3R,5S)-1-(tert-butoxycarbonyl)-3-(tert-butyldimethylsiloxy)-5-(2-furyl)pyrrolidin-2-one 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 51-35-4 4R-4-hydroxyproline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 267420-66-6 (3R,5S)-3-(tert-butyldimethylsiloxy)-5-(2-furyl)pyrrolidin-2-one 
• 267420-56-4 (3R,5S)-1-benzyl-5-(2-furyl)-3-hydroxypyrrolidin-2-one 
• 267420-64-4 (3R,5S)-5-(2-furyl)-3-hydroxypyrrolidin-2-one 
• 114676-91-4 1-tert-butyl 2-methyl (2S,4R)-4-{[tert-butyl(dimethyl)silyl]oxy}pyrrolidine-1,2-dicarboxylate 

Downstream Products

• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 
• 1311406-92-4 C₁₇H₁₆N₆O₂ 
• 1311407-00-7 C₁₈H₂₇NO₃Si 
• 1311407-01-8 C₂₉H₂₉N₇O₆ 
• 1311407-03-0 C₂₁H₂₂N₆O₄ 
• 1311407-04-1 3S-(2-(N-isobutyrylguanin-9-yl))-5S-(hydroxymethyl)-N-benzyl-2-pyrrolidinone 
• 1311407-05-2 C₁₇H₁₆N₆O₃ 
• 170012-71-2 methyl (2S,4R)-4-hydroxy-5-oxopyrrolidine-2-carboxylate 
• 884-68-4 Phyllochrysin 
• 1448348-14-8 (2S)-4-(tert-Butyldimethylsilyloxy)-N-(1-(2-chlorophenyl)-2-(3,3-difluorocyclobutyl-amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(3-fluorophenyl)-4-methyl-5-oxopyrrolidine-2-carboxamide 
• 1448348-13-7 (2S)-4-(tert-Butyldimethylsilyloxy)-N-(1-(2-chlorophenyl)-2-(3,3-difluorocyclobut-ylamino)-2-oxoethyl)-N-(3-fluorophenyl)-4-methyl-5-oxopyrrolidine-2-carboxamide 
• 367966-41-4 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-5-oxopyrrolidine-1,2-dicarboxylate 

Relevant articles and documents

Stereoselective synthesis and biological evaluations of novel 3′-deoxy-4′-azaribonucleosides as inhibitors of hepatitis C virus RNA replication

3′-Deoxy-4′-azaribonucleosides (15a-d) were synthesized starting from the commercially available (4R)-trans-4-hydroxy-L-proline 7. From biological evaluations, 15b and 15d emerged as potent inhibitors of HCV replication on a replicon assay. These findings demonstrate that synthesized pyrrolidine nucleosides represent a new template for antiviral or other biological studies and could be considered for novel combination therapy against HCV infection using nucleoside inhibitors and non-nucleoside inhibitors of HCV NS5B.

Regioselective oxidation of N-alkylpyrrolidines to pyrrolidin-5-ones by RuCl3/NaIO4

RuCl3/NaIO4 under EtOAc/H2O biphasic conditions, selectively oxidizes the Nα-endo-methylene group of pyrrolidine derivatives, without affecting the exo-methylene group adjacent to the N-heteroatom.

Tricyclic-Carbocyclic RORγt Inverse Agonists - Discovery of BMS-986313

SAR efforts directed at identifying RORγt inverse agonists structurally different from our clinical compound 1 (BMS-986251) led to tricyclic-carbocyclic analogues represented by 3-7 and culminated in the identification of 3d (BMS-986313), with structural differences distinct from 1. The X-ray co-crystal structure of 3d with the ligand binding domain of RORγt revealed several key interactions, which are different from 1. The in vitro and in vivo PK profiles of 3d are described. In addition, we demonstrate robust efficacy of 3d in two preclinical models of psoriasis - the IMQ-induced skin lesion model and the IL-23-induced acanthosis model. The efficacy seen with 3d in these models is comparable to the results observed with 1.

TRICYCLIC SULFONES AS ROR GAMMA MODULATORS

There are described RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF

Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

Synthesis of 3-guaninyl- and 3-adeninyl-5-hydroxymethyl-2-pyrrolidinone nucleosides

l- And d-glutamic acids, as well as trans-4-hydroxy-l-proline, are converted to the corresponding 3-guaninyl-5-hydroxymethyl-2-pyrrolidinone (4) or 3-adeninyl-5-hydroxymethyl-2-pyrrolidinone (5) nucleoside analog. The protecting group used to block the lactam nitrogen in key intermediates has a significant effect on the diastereoselectivity of the coupling reaction with adenine or guanine.

The asymmetric total synthesis of (-)-securinine

The alkaloid (-)-securinine was synthesized in 18 steps and 16% overall yield from trans-4-hydroxy-l-proline. The Royal Society of Chemistry.